Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study
Peter J. Weiden, Alan Breier, Sarah Kavanagh, Andrew C. Miller, Stephen K. Brannan, Steven M. Paul
Dive into the research topics of 'Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study'. Together they form a unique fingerprint.